CJC-1295

CJC-1295 is a synthetic peptide that modulates the growth hormone (GH) and insulin-like growth factor-1 (IGF-1) axis. Based on available evidence, clinical applications remain limited and largely investigational.

Investigated Medical Applications

HIV-Associated Lipodystrophy: The most documented clinical trial (NCT00267527) evaluated CJC-1295 specifically for treating visceral obesity in HIV patients. However, this Phase 2 study was terminated, and no efficacy or safety results from this trial are publicly available in the provided evidence.

Off-Label and Investigational Uses

Current literature suggests CJC-1295 is being explored across several areas, though robust clinical evidence remains limited:

Sports Medicine and Performance: Multiple 2026 reviews indicate CJC-1295 is used in sports medicine contexts, particularly for musculoskeletal injuries and athletic performance enhancement. However, these sources emphasize the gap between clinical evidence and actual patient use, noting that many applications lack sufficient safety and efficacy data.

Anti-Aging and Metabolic Applications: Recent reviews mention CJC-1295's use in aesthetic medicine, metabolic conditions, and gerontology applications focused on healthy aging. The therapeutic rationale centers on its ability to stimulate growth hormone release, potentially addressing age-related GH decline.

Orthopedic Applications: Some literature references its use in orthopedic and musculoskeletal contexts, though specific clinical outcomes data is not detailed in the available evidence.

Evidence Limitations

The current evidence base reveals significant gaps between theoretical applications and proven clinical efficacy. Multiple reviews from 2026 consistently highlight concerns about the use of GH-modulating peptides like CJC-1295, noting limited clinical trial data, safety questions, and regulatory challenges. The terminated HIV study represents the only identified formal clinical trial, providing no outcome data.

Disclaimer: This information is for educational purposes only and does not constitute medical advice. CJC-1295 remains largely investigational, and patients should consult qualified healthcare providers regarding any peptide therapy considerations.